Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM.
Bahlis NJ, et al. Among authors: chu mp.
Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2.
Nat Med. 2023.
PMID: 37783970
Free PMC article.
Clinical Trial.